*Pharmacy opening hours: Monday – Friday 9am – 5pm. Saturday & Sunday 9am – 1pm. |
Accesses emails between 9am-5pm Monday to Friday and runs a daily MDT to discuss cases at 12:30 via Microsoft Teams.
Stores completed patient proforma on the confidential Microsoft Teams channel and records patient details in the Paediatric nMABs database.
Liaises with RHC hospital co-ordinator to arrange a bed space and nursing support for treatment.
Informs ED of expected admission of SARS-CoV-2 PCR positive patient.
Sotrovimab (Xevudy) |
|
Preparations available |
Xevudy (sotrovimab) 500mg/8ml concentrate for solution for infusion |
Dose |
All patients >12yrs and >40kg A single dose of 500mg, given by IV infusion |
Methods of administration |
Intravenous (IV) infusion over 30 minutes The final preparation for infusion must be administered via a 0.2 micron low protein binding in-line filter supplied by pharmacy with the Sotrovimab. Do NOT administer as an IV push/bolus or via any other route. |
Compatibility and stability |
Fluids 0.9% sodium chloride OR 5% glucose Drugs (Y-site compatibility) Sotrovimab should be given through a dedicated line and should not be mixed/administered with other medicinal products. Stability The diluted solution is intended to be used immediately. If immediate administration is not possible the diluted solution may be stored:
OR
Protect from light. pH & Osmolarity pH 6 (undiluted) 290mOsm/kg (undiluted) |
Preparation and administration |
Dilution and administration instructions
|
Points to note |
|
Adverse reaction and suggested monitoring |
Sotrovimab is a black triangle drug. All suspected adverse reaction must be reported via the COVID-19 Yellow Card reporting site or Yellow Card App. |
Interactions |
No interaction studies have been performed. Sotrovimab is not renally excreted nor is it metabolised by cytochrome P450 enzymes, therefore interaction with concomitant therapies that are renally excreted or that are substrates, inducers or inhibitors or CYP enzymes are unlikely. |
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARSCoV-2 Neutralizing Antibody Sotrovimab [published online ahead of print, 2021 Oct 27]. N Engl J Med. 2021
Last reviewed: 03 March 2022
Next review: 31 March 2023
Author(s): Dr Conor Doherty; Dr Katherine Longbottom; Susan Kafka
Author Email(s): Conor.doherty@ggc.scot.nhs.uk
Approved By: Infectious Diseases Group